These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24028894)

  • 1. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.
    Zeng L; Li J; Wang Y; Qian C; Chen Y; Zhang Q; Wu W; Lin Z; Liang J; Shuai X; Huang K
    Nanomedicine; 2014 Feb; 10(2):463-72. PubMed ID: 24028894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
    Wang F; Zhang Z
    Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
    Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
    Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
    Mehta A; Dalle Vedove E; Isert L; Merkel OM
    Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copolymer of poly(ethylene glycol) and poly(L-lysine) grafting polyethylenimine through a reducible disulfide linkage for siRNA delivery.
    Li J; Cheng D; Yin T; Chen W; Lin Y; Chen J; Li R; Shuai X
    Nanoscale; 2014; 6(3):1732-40. PubMed ID: 24346086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
    Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
    Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells.
    Li C; Ge M; Yin Y; Luo M; Chen D
    Mol Cell Biochem; 2012 Nov; 370(1-2):127-39. PubMed ID: 22868929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
    Costa-Cabral S; Brough R; Konde A; Aarts M; Campbell J; Marinari E; Riffell J; Bardelli A; Torrance C; Lord CJ; Ashworth A
    PLoS One; 2016; 11(2):e0149099. PubMed ID: 26881434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
    Sasayama Y; Hasegawa M; Taguchi E; Kubota K; Kuboyama T; Naoi T; Yabuuchi H; Shimai N; Asano M; Tokunaga A; Ishii T; Enokizono J
    J Control Release; 2019 Oct; 311-312():245-256. PubMed ID: 31505222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuned Density of Anti-Tissue Factor Antibody Fragment onto siRNA-Loaded Polyion Complex Micelles for Optimizing Targetability into Pancreatic Cancer Cells.
    Min HS; Kim HJ; Ahn J; Naito M; Hayashi K; Toh K; Kim BS; Matsumura Y; Kwon IC; Miyata K; Kataoka K
    Biomacromolecules; 2018 Jun; 19(6):2320-2329. PubMed ID: 29767505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
    Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
    J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
    Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
    Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
    Zhang W; Li H; Yang Y; Liao J; Yang GY
    Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEG-detachable cationic polyaspartamide derivatives bearing stearoyl moieties for systemic siRNA delivery toward subcutaneous BxPC3 pancreatic tumor.
    Kim HJ; Oba M; Pittella F; Nomoto T; Cabral H; Matsumoto Y; Miyata K; Nishiyama N; Kataoka K
    J Drug Target; 2012 Jan; 20(1):33-42. PubMed ID: 22066783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
    Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
    Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy.
    Xu Y; Yu Z; Fu H; Guo Y; Hu P; Shi J
    ACS Appl Mater Interfaces; 2022 May; 14(19):21836-21847. PubMed ID: 35512029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.